Clinical Trials Logo
  1. Home
  2. Recurrent Small Cell Lung Cancer
  3. NCT00168922

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Recurrent Small Cell Lung Cancer Clinical Trial

Official title:
Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy

Clinical Trial Summary

Determination of response rate Assessment of toxicity and determination of "time to progression"

Clinical Trial Description

Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00168922
Study type Interventional
Source Charite University, Berlin, Germany
Contact Ulrich Keilholz, MD
Phone +49-30-8445-3596
Email ulrich.keilholz@charite.de
Status Recruiting
Phase Phase 2
Start date February 2001
Completion date December 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Completed NCT01931787 - CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Phase 1
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Terminated NCT04610658 - Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Phase 1
Completed NCT00773955 - R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer Phase 2
Completed NCT00528645 - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT00028535 - Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors Phase 1
Recruiting NCT03732846 - Anlotinib in Treatment of Recurrent Small Cell Lung Cancer Phase 2
Active, not recruiting NCT00828139 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Phase 2
Completed NCT00086827 - Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2
Completed NCT00052949 - Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer Phase 2
Withdrawn NCT01325753 - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body N/A
Not yet recruiting NCT05162196 - The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Terminated NCT00088933 - Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer Phase 1
Completed NCT00020202 - FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer Phase 2
Completed NCT01901653 - Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT00182689 - Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT01457469 - Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer Phase 1
Completed NCT00098956 - 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer Phase 2